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Supplementary Materials
Sections S1 and S2. Characterization of fluorescent lipid analogs Scanning STED FCS requires dedicated lipid analogs with photostable and bright dye labels such as Atto647N or KK114. Figure S1 shows the structures of the lipid analogs used throughout the present study. These analogs have been used multiple times before and in their cases the dye label shown to have minimal influence on the lipids' membrane interaction dynamics (34-37) as confirmed by using classical spot FCS ( fig. S2 ), highlighting that the mobility of these lipid analogs in CD4+ T-cells was comparable between different dye labels, specifically to the mobility observed with corresponding BODIPY labelled lipids that we previously used to monitor the effect of Gag self-assembly on model membranes (10) 
Section S3. MHC-I mobility at HIV-1 assembly sites in NL4.3 Gag-iGFP HIV-1-infected

Jurkat T cells
In order to further reinforce the idea that our experiments are not observing fully assembled/budded viruses on the cell membrane, we have performed an experiment measuring MHC-I mobility at HIV-1 virus assembly sites in infected Jurkat T-cells. For the observation of MHC-I mobility, NL4.3 Gag-iGFP infected cells were stained for MHC-I in suspension at 16 °C using W6/32 anti-MHC-I Fab fragments and anti-human Abberior STAR RED (KK114) conjugated Fab fragments for 1 h each in 0.5% BSA/L-15 Medium (3).
Mobility analysis inside and outside selected virus assembly sites shows that there is no significant MHC-I mobility change at these sites compared to areas outside and uninfected control cells. In a previous study (3), we shown that MHC-I mobility is highly reduced on fully assembled and budded viruses (Dmedian = 0.0027 μm 2 /s). These results indicate that virus assembly sites analysed in this study do not represent fully assembled and budded virus particles. Small mobility reduction seen between inside and outside assembly site areas may be due to the early stages of the virus assembly beginning to affect MHC-I diffusion in these areas. 
Section S4. STED microscope calibration
The diameters of the observation spots employed in the scanning STED-FCS was estimated at 37 °C following a standard calibration procedure on supported lipid bilayers (SLBs) (61), comparing transit times of freely diffusing fluorescent lipid (KK114-DPPE) in confocal and STED microscopy modes ( fig. S4 ). box) the generated Gag aggregation sites. We observed a significant decrease in ATTO647N-PI(4,5)P2 lateral mobility at (Da = 0.15 µm 2 .s -1 ) compared to outside (Da = 1.1 µm 2 .s -1 ) the sites or before the addition of Gag (Da = 0.95 µm 2 .s -1 ), highlighting strong trapping of ATTO647N-PI(4,5)P2 in lipid domains generated by Gag.
We then applied the confinement index calculation to determine the enrichment of ATTO647N-PI(4,5)P2 in Gag induced clusters. We obtained values in line with either HIV-1 infected cells or HIV-1 Gag.eGFP transfected cells. (Figs. 2 and 3 We attempted to transfect Jurkat T cells, using electroporation, with a mixture of tagged and untagged Gag expressing plasmids, similarly to studies done on highly transfectable adherent cell lines, such as HeLa or 293T cells (see Jouvenet et al., (62) and Ivanchenko et al., (32) ), but never on CD4 T cells. When electroporated with 2 plasmids we observed, using anti-CA (p24) immunoblots, that one of the plasmids is better expressed than the other: here, it is the pGag plasmid -producing unlabelled Gag proteins ( fig. S6a ). Moreover, with a ratio of 1 to 3 Gag.eGFP/Gag expressing plasmids we were not able to detect GFP(+) cells producing fluorescent VLPs and none of them were producing detectable virus assembly sites. This lack of production of fluorescent dots (virus assembly) at their cell surface thus prevents us from doing STED-FCS in and out of the virus assembly sites. In these conditions Gag.eGFP stays diffuse in the cytosol even 40h post-transfection, indicating probably that the unlabelled Gag protein is assembling preferentially, leaving the Gag.eGFP poorly incorporated into the viral budding site ( fig. S6b ). This data indicates that we are unable to do a plasmid mixture experiments on electroporated Jurkat T cells.
Nonetheless, we believe that Gag.eGFP only experiment is still useful in the context of our study. This is because, while constructs such as pKHIV.eGFP or NL43.eGFP indeed require a rescue (50% of untagged Gag) to get a fully infectious virus, early studies using these constructs suggest that the infectivity defects in Gag.eGFP-only particles arise from incorrect Gag processing (maturation) following assembly rather than Gag assembly itself (63).
Furthermore, in a recently study (33), we have shown that in Jurkat T cells expressing 100% mEOS2-tagged(i)Gag, we were able to monitor at the single molecule level, the kinetic of Gag assembly and it was found to resemble the one described in HeLa cells (5 min of assembly + 10 min of particle residence at the cell membrane and release).
We would also like to emphasise that similar lipid mobility results were also obtained using fully infectious NL43 Gag.iGFP plasmid. This plasmid is described in the study of Hubner et al. (31), which characterize fully infectious NL4.3 Gag.iGFP virus particles. Although the authors do not comment on the assembly and release competency of the particles they indicate
